Research progress of long non-coding RNA UCA1 in tumor

doi:10.3760/cma.j.issn.1673-422X.2016.01.008

Abstract

Abstract: As a proto-oncogene, urothelial carcinoma antigen 1 (UCA1) is highly expressed in many human tumors such as bladder cancer, gastric cancer, breast cancer, ovarian cancer and brain glioma, which shows important application value in the diagnosis, treatment and prognosis of tumor. Studies show that UCA1 can promote tumor cell proliferation through multiple signaling pathways and molecular mechanisms, which may become a new potential target for the diagnosis and treatment of tumor.

Key words: RNA, Neoplasms, Urothelial carcinoma antigen 1

Shi Youyang, Qian Yayun. Research progress of long non-coding RNA UCA1 in tumor[J]. Journal of International Oncology, 2016, 43(1): 29-31.

References

［1］ Wang XS, Zhang Z, Wang HC, et al. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladdercarcinoma［J］. Clin Cancer Res, 2006, 12 (16): 4851-4858. DOI:10.1158/10780432.CCR-06-0134. ［2］ Xue M, Li X, Wu W, et al. Upregulation of long noncoding RNA urothelial carcinoma associated 1 by CCAAT/enhancer binding protein α contributes to bladder cancer cell growth and reduced apoptosis［J］. Oncol Rep, 2014, 31(5): 1993-2000. DOI:10.3892/or.2014.3092. ［3］ Xie XJ, Li X, Wang F, et al. Cellular localization and tissue expression pattern of UCA1, a noncoding RNA［J］. Nan Fang Yi Ke DaXue Xue Bao, 2010, 30(1): 57-60. ［4］ Rafiee P, Shi Y, Su J, et al. Erythropoietin protects the infant heart against ischemiareperfusion injury by triggering multiple signaling pathways［J］. Basic Res Cardiol, 2005, 100(3): 187-197. ［5］ Codolo G, Munari F, Fassan M, et al. Evaluation of the efficacy of the H. pylori protein HPNAP as a therapeutic tool for treatment of bladder cancer in an orthotopic murine model［J］. J Vis Exp, 2015, 99: e52743. DOI:10.3791/52743. ［6］ Zhang Z, Hao H, Zhang CJ, et al. Evaluation of novel gene UCA1 as a tumor biomarker for the detection of bladder［J］. Zhonghua Yi Xue Za Zhi, 2012, 92(6): 384-387. ［7］ Wang F, Li X, Xie X, et al. UCA1, a nonproteincoding RNA upregulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion［J］. FEBS Letters, 2008, 582(13): 1919-1927. DOI:10.1016/j.febslet.2008.05.012. ［8］ Fan Y, Shen B, Tan M, et al. Long noncoding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling［J］. FEBS J, 2014, 281(7): 1750-1758. DOI:10.1111/febs.12737. ［9］ Yang C, Li X, Wang Y, et al. Long noncoding RNA UCA1 regulated cell cycle distribution via CREB through PI3K dependent pathway in bladder carcinoma cells［J］. Gene, 2012, 496(1): 8-16. DOI:10.1016/j.gene.2012.01.012. ［10］ Wang X, Gong X, Jin B, et al. Long noncoding RNA urothelial carcinoma associated 1 induces cell replication by inhibiting BRG1 in 5637 cells［J］. Oncology Rep, 2014, 32(3): 1281-1290. DOI:10.3892/or.2014.3309. ［11］ Gu W, Gao T, Sun Y, et al. LncRNA expression profile reveals the potential role of lncRNAs in gastric carcinogenesis［J］. Cancer Biomark, 2015, 15(3): 249-258. DOI:10.3233/CBM-150460. ［12］ Han Y, Yang YN, Yuan HH, et al. UCA1, a long noncoding RNA upregulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution［J］. Pathology, 2014, 46(5): 396-401. DOI:10.1097/PAT.0000000000000125. ［13］ Li JY, Ma X, Zhang CB. Overexpression of long noncoding RNA UCA1 predicts a poor prognosis in patients with esophageal squamous cell carcinoma［J］. Int J Clin Exp Pathol, 2014, 7(11): 7938-7944. ［14］ Huang J, Zhou N, Watabe K, et al. Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1)［J］. Cell Death Dis, 2014, 5：e1008. DOI:10.1038/cddis.2013.541. ［15］杨慧, 余敏敏, 陆晓媛. 长链非编码RNA在宫颈癌及宫颈上皮内瘤样病变中的表达［J］. 江苏医药, 2014, 40(22): 2685-2688. ［16］ Lim D, Olive E. Precursors and pathogenesis of ovarian carcinoma［J］. Pathology, 2013, 45(3): 229-242. DOI:10.1097/PAT.0b013e32835f2264. ［17］ Wang F, Zhou J, Xie X, et al. Involvement of SRPK1 in cisplatin resistance related to long noncoding RNA UCA1 in human ovarian cancer cells［J］. Neoplasma, 2015, 62(3): 432-438. DOI:10.4149/neo/2015/051. ［18］ Gerstner ER, Batchelor TT. Imaging and response criteria in gliomas［J］. Curr Opin Oncol, 2010, 22(6): 598-603. DOI:10.1097/CCO.0b013e32833de96e. ［19］孙阳. 长链非编码RNA在脑胶质瘤中差异表达的相关研究［D］. 长春: 吉林大学, 2014. ［20］ Tsang WP, Wong TW, Cheung AH, et al. Induction of drug resistance and transformation in human cancer cells by the noncodingRNA CUDR［J］. RNA, 2007, 13(6): 890-898. DOI:10.1261/rna.359007. ［21］ Tian Y, Zhang X, Hao Y, et al. Potential roles of abnormally expressed long noncoding RNA UCA1 and Malat-1 in metastasis of melanoma[J]. Melanoma Res, 2014, 24(4): 335-341. DOI:10.1097/CMR.0000000000000080. ［22］ Fang Z, Wu L, Wang L, et al. Increased expression of the long noncoding RNA UCA1 in tongue squamous cell carcinomas: a possible correlation with cancer metastasis［J］. Oral Surg Oral Med Oral Pathol Oral Radiol, 2014, 117(1): 8995. DOI:10.1016/j.oooo.2013.09.007.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.